Clinical observation of ambroxol hydrochloride combined with procaterol hydrochloride in the treatment of Mycoplasma pneumoniae pneumonia in children
扫码查看
点击上方二维码区域，可以放大扫码查看
原文链接
万方数据
目的 探讨盐酸氨溴索联合盐酸丙卡特罗治疗小儿肺炎支原体肺炎(MPP)的临床效果。 方法 抽取2019年12月至2022年3月河南大学淮河医院收治的MPP患儿92例，采用随机数字表法分为丙卡特罗组与氨溴索组，每组46例。氨溴索组采用盐酸氨溴索治疗，丙卡特罗组在氨溴索组基础上采用盐酸丙卡特罗治疗。比较两组治疗效果、症状消失时间、炎症因子[C反应蛋白(CRP)、干扰素-γ(IFN-γ)、白细胞介素-2(IL-2)]水平、免疫功能[T淋巴细胞(CD3＋、CD4＋、CD8＋)]及不良反应发生率。 结果 丙卡特罗组总有效率(93.48%，43/46)高于氨溴索组(78.26%，36/46)，P<0.05。丙卡特罗组症状消失时间短于氨溴索组(P<0.05)。治疗后，丙卡特罗组CRP、IFN-γ、IL-2水平低于氨溴索组(P<0.05)；治疗后，丙卡特罗组CD3＋、CD4＋高于氨溴索组，CD8＋低于氨溴索组(P<0.05)。丙卡特罗组不良反应发生率(8.70%，4/46)与氨溴索组(4.35%，2/46)比较差异未见统计学意义(P>0.05)。 结论 盐酸氨溴索联合盐酸丙卡特罗治疗MPP的效果较好，能减轻机体炎症，提高免疫功能，缓解临床症状，且治疗安全性良好。 Objective To investigate the clinical effect of ambroxol hydrochloride combined with procaterol hydrochloride in the treatment of Mycoplasma pneumoniae pneumonia (MPP) in children. Methods A total of 92 children with MPP treated in Huaihe Hospital of Henan University from December 2019 to March 2022 were selected, and they were divided into procaterol group and ambroxol group by random number table method, with 46 cases in each group. The ambroxol group was treated with ambroxol hydrochloride, while the procaterol group was treated with procaterol hydrochloride based on the treatment of the ambroxol group. The treatment efficacy, symptom disappearance time, levels of inflammatory factors, including C-reactive protein (CRP), interferon-γ (IFN-γ) and interleukin-2 (IL-2), immune function assessed by T lymphocytes, including cluster of differentiation 3+ (CD3+ ), cluster of differentiation 4+ (CD4+ ) and cluster of differentiation 8+ (CD8+ ), and incidence of adverse reactions of the two groups were compared. Results The total effective rate of the procaterol group (93.48%, 43/46) was higher than that of the ambroxol group (78.26%, 36/46), P<0.05. The symptom disappearance time in the procaterol group was shorter than that in the ambroxol group (P<0.05). After treatment, the levels of CRP, IFN-γ and IL-2 in the procaterol group were lower than those in the ambroxol group (P<0.05). After treatment, CD3+ and CD4+ in the procaterol group were higher than those in the ambroxol group, while CD8+ was lower than that in the ambroxol group (P<0.05). There was no significant difference in the incidence of adverse reactions between the procaterol group (8.70%, 4/46) and the ambroxol group (4.35%, 2/46),P>0.05. Conclusions Ambroxol hydrochloride combined with procaterol hydrochloride has a good effect in the treatment of MPP. It can reduce inflammation, improve immune function, and alleviate clinical symptoms, which has good treatment safety.
Objective To investigate the clinical effect of ambroxol hydrochloride combined with procaterol hydrochloride in the treatment of Mycoplasma pneumoniae pneumonia (MPP) in children. Methods A total of 92 children with MPP treated in Huaihe Hospital of Henan University from December 2019 to March 2022 were selected, and they were divided into procaterol group and ambroxol group by random number table method, with 46 cases in each group. The ambroxol group was treated with ambroxol hydrochloride, while the procaterol group was treated with procaterol hydrochloride based on the treatment of the ambroxol group. The treatment efficacy, symptom disappearance time, levels of inflammatory factors, including C-reactive protein (CRP), interferon-γ (IFN-γ) and interleukin-2 (IL-2), immune function assessed by T lymphocytes, including cluster of differentiation 3+ (CD3+ ), cluster of differentiation 4+ (CD4+ ) and cluster of differentiation 8+ (CD8+ ), and incidence of adverse reactions of the two groups were compared. Results The total effective rate of the procaterol group (93.48%, 43/46) was higher than that of the ambroxol group (78.26%, 36/46), P<0.05. The symptom disappearance time in the procaterol group was shorter than that in the ambroxol group (P<0.05). After treatment, the levels of CRP, IFN-γ and IL-2 in the procaterol group were lower than those in the ambroxol group (P<0.05). After treatment, CD3+ and CD4+ in the procaterol group were higher than those in the ambroxol group, while CD8+ was lower than that in the ambroxol group (P<0.05). There was no significant difference in the incidence of adverse reactions between the procaterol group (8.70%, 4/46) and the ambroxol group (4.35%, 2/46),P>0.05. Conclusions Ambroxol hydrochloride combined with procaterol hydrochloride has a good effect in the treatment of MPP. It can reduce inflammation, improve immune function, and alleviate clinical symptoms, which has good treatment safety.
Pneumonia, MycoplasmaAmbroxol hydrochlorideProcaterol hydrochloridePulmonary function
万方数据
